Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’

A veteran biotechnology executive, Jonas had spent nine years at neuroscience drug developer Sage Therapeutics. Hired as CEO in 2013, Jonas helped build Sage from a tiny startup into a large, publicly traded company that brought to market the first approved drug for postpartum depression. A second depression drug that’s part of a $3 billion alliance with Biogen could be submitted to regulators this month.